Sucralfate attenuates gastric mucosal lesions and increased vascular permeability induced by ischaemia and reperfusion in rats.
Recent evidence suggests that oxygen-derived free radicals are involved in mediating gastric microvascular and parenchymal cell injuries induced by ischaemia and reperfusion. Therefore, the effect of the locally acting anti-ulcer drug, sucralfate, was studied on ischaemia and reperfusion (e.g. induced gastric lesions, intraluminal bleeding, changes in vascular permeability and non-protein sulfhydryl levels in the rat stomach). Allopurinol was used as a known standard antioxidant drug. Rats were subjected to 30 min of gastric ischaemia in the presence of 100 mmol/L hydrochloric acid and reperfusion periods of 15, 30 or 60 min duration. The gastric lesions were assessed microscopically under an inverted microscope. The vascular permeability was quantified by measuring the extravasated Evans blue in the stomach. There were significantly greater numbers of gastric lesions, intraluminal bleeding and leakage of Evans blue during all reperfusion periods as compared with those of ischaemia, with maximum effects occurring at 60 min following reperfusion. Pretreatment with sucralfate (31.25-250 mg/kg, p.o.) or allopurinol (12.5-50 mg/kg, i.p.) 30 min before the procedure, dose-dependently reduced the gastric lesions, intraluminal bleeding, and decreased the vascular permeability induced by ischaemia and reperfusion. Furthermore, sucralfate dose-dependently reverses the ischaemia and reperfusion-induced depletion of mucosal non-protein sulfhydryl levels and inhibited the superoxide radical production in both cell-free xanthine-xanthine oxidase and in the stimulated polymorphonuclear cellular systems. These results suggest that the protection produced by sucralfate against gastric injury may be due to its antioxidant effects.
al-Swayeh
O A
OA
Department of Medical Pharmacology, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
al-Humayyd
M S
MS
Mustafa
A A
AA
al-Tuwaijri
A S
AS
al-Rashed
R S
RS
Ali
A T
AT
D000493:Allopurinol / Q000008:administration & dosage; D000818:Animals; D002199:Capillary Permeability / Q000187:drug effects*; D004396:Coloring Agents; D004305:Dose-Response Relationship, Drug; D005070:Evans Blue; D005753:Gastric Mucosa / Q000098:blood supply / Q000737:chemistry / Q000187:drug effects* / Q000473:pathology; D007511:Ischemia / Q000473:pathology*; D008297:Male; D009504:Neutrophils; D051381:Rats; D017208:Rats, Wistar; D015427:Reperfusion Injury / Q000517:prevention & control*; D013392:Sucralfate / Q000494:pharmacology*; D013438:Sulfhydryl Compounds / Q000032:analysis; D013482:Superoxide Dismutase / Q000378:metabolism; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology; D013997:Time Factors; D014969:Xanthine Oxidase / Q000378:metabolism; D014970:Xanthines / Q000378:metabolism
D004396:Coloring Agents; D013438:Sulfhydryl Compounds; D014970:Xanthines; D005070:Evans Blue; D013392:Sucralfate; D000493:Allopurinol; D013482:Superoxide Dismutase; D014969:Xanthine Oxidase; D013755:Tetradecanoylphorbol Acetate